The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Phase I Study of SS1P, a Recombinant Anti-Mesothelin Immunotoxin Given as a Bolus I.V. Infusion to Patients with Mesothelin-Expressing Mesothelioma, Ovarian, and Pancreatic Cancers
Open accessAbstract
Purpose: To determine the toxicities, maximum tolerated dose (MTD) and pharmacokinetics of the recombinant immunotoxin SS1P (anti-mesothelin dsFv-PE38) in patients with mesothelin-expressing cancers. Experimental Design: SS1P given as a 30-min i.v. infusion every other day (QOD) for six or three doses was administered to 34 patients with advanced mesothelioma (n = 20), ovarian (n = 12), and pancreatic (n = 2) cancer. Results: The initial cohort of 17 patients received SS1P QOD × 6 doses and the MTD was 18 μg/kg/dose. Dose-limiting toxicities (DLT) included grade 3 uticaria (one patient) and grade 3 vascular leak syndrome (two patients). To allow further SS1P dose escalation, 17 patients were treated on the QOD × 3 schedule and the MTD was 45 μg/kg/dose. The DLT was grade 3 pleuritis and was seen in two of two patients treated at a dose of 60 μg/kg and in one of nine patients treated at a dose of 45 μg/kg. At the MTD of 45 μg/kg, the mean Cmax of SS1P was 483 ng/mL and half-life was 466 min. Of the 33 evaluable patients treated, 4 had minor responses, 19 had stable disease (including 2 with resolution of ascites), and 10 had progressive disease. Conclusions: SS1P is well tolerated with pleuritis as the DLT at the highest dose level. Evidence of clinical activity was noted in a group of heavily pretreated patients. Phase II clinical trials of SS1P are being planned for malignant mesothelioma and other mesothelin-expressing malignancies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Barriers to Drug Delivery in Solid Tumors
Jain, R. K. (1994) · Scientific American · doi:10.1038/scientificamerican0794-58 · Cited by 1,069
Chang, K., & Pastan, I. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.1.136 · Cited by 745
Self-citationOlsen, E., Duvic, M., Frankel, A., Kim, Y., Martin, A., Vonderheid, E., Jegasothy, B., Wood, G., Gordon, M., Heald, P., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.2.376 · Cited by 609
Argani, P., Iacobuzio–Donahue, C. A., Ryu, B., Rosty, C., Goggins, M., Wilentz, R. E., Murugesan, S. R., Leach, S. D., Jaffee, E. M., Yeo, C. J., et al. (2001) · PubMed · Cited by 574
Binding of Ovarian Cancer Antigen CA125/MUC16 to Mesothelin Mediates Cell Adhesion
Rump, A., Morikawa, Y., Tanaka, M., Minami, S., Umesaki, N., Takeuchi, M., & Miyajima, A. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m312372200 · Cited by 572
Mesothelin-family proteins and diagnosis of mesothelioma
Robinson, B. W., Creaney, J., Lake, R., Nowak, A., Musk, A. W., de Klerk, N., Winzell, P., Hellstrom, K. E., & Hellstrom, I. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14794-0 · Cited by 534
Pastan, I., Hassan, R., FitzGerald, D. J., & Kreitman, R. J. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1891 · Cited by 528
Self-citationHassan, R., Bera, T., & Pastan, I. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0801 · Cited by 441
Self-citationGubbels, J. A., Belisle, J., Onda, M., Rancourt, C., Migneault, M., Ho, M., Bera, T. K., Connor, J., Sathyanarayana, B. K., Lee, B., et al. (2006) · Molecular Cancer · doi:10.1186/1476-4598-5-50 · Cited by 422
Self-citationKreitman, R. J., Wilson, W. H., White, J. D., Stetler-Stevenson, M., Jaffe, E. S., Giardina, S., Waldmann, T. A., & Pastan, I. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.8.1622 · Cited by 420
Self-citation
Cited by
Carpenito, C., Milone, M. C., Hassan, R., Simonet, J. C., Lakhal, M., Suhoski, M. M., Varela-Rohena, A., Haines, K. M., Heitjan, D. F., Albelda, S. M., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813101106 · Cited by 888
Self-citationBeatty, G. L., Haas, A. R., Maus, M. V., Torigian, D. A., Soulen, M. C., Plesa, G., Chew, A., Zhao, Y., Levine, B. L., Albelda, S. M., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0170 · Cited by 864
Malignant Pleural Mesothelioma
Tsao, A. S., Wistuba, I., Roth, J. A., & Kindler, H. L. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.8523 · Cited by 481
Self-citationMesothelin-Targeted CARs: Driving T Cells to Solid Tumors
Morello, A., Sadelain, M., & Adusumilli, P. S. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0583 · Cited by 477
Mesothelin targeted cancer immunotherapy
Hassan, R., & Ho, M. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2007.08.028 · Cited by 340
Self-citation
Metadata
- Authors
- Hassan, R., Bullock, S., Premkumar, A., Kreitman, R. J., Kindler, H., Willingham, M. C., & Pastan, I.
- Venue
- Clinical Cancer Research
- Published
- 2007-09-01
- Volume
- 13
- Issue
- 17
- Pages
- 5144-5149
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2101371847
- Cited by
- 379
- References
- 23
- FWCI
- 7.02
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phase I Study of SS1P, a Recombinant Anti-Mesothelin Immunotoxin Given as a Bolus I.V. Infusion to Patients with Mesothelin-Expressing Mesothelioma, Ovarian, and Pancreatic Cancers. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-07-0869
- The paper
- Hassan, R., Bullock, S., Premkumar, A., Kreitman, R. J., Kindler, H., Willingham, M. C., & Pastan, I. (2007). Phase I Study of SS1P, a Recombinant Anti-Mesothelin Immunotoxin Given as a Bolus I.V. Infusion to Patients with Mesothelin-Expressing Mesothelioma, Ovarian, and Pancreatic Cancers. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-07-0869
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.